Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,373 people get ACT articles and Market Currents by email alert.
Get email alerts on ACT »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
Watson Is Still Strong Despite A Slowing Generic Drug MarketFreedonia Freelance • Tue, Dec 11, 2012 -
-
-
-
-
Watson Pharmaceuticals: Earnings PreviewZacks Investment Research • Tue, Jul 24, 2012 -
-
-
-
-
Accretive Acquisitions Likely For Watson PharmaceuticalsTakeover Analyst • Sun, Oct 9, 2011
-
Watson Benefits From New PartnershipsJim Van Meerten • Wed, Jun 22, 2011
-
Watson Pharmaceuticals Earnings PreviewZacks Investment Research • Tue, Apr 26, 2011
-
Watson Pharmaceuticals: In-Depth Analysis for the December 2010 QuarterNeil Carvin • Sun, Feb 20, 2011 -
Watson Pharmaceuticals: Looking Ahead to December 2010 Quarterly ResultsNeil Carvin • Fri, Dec 31, 2010
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
Valeant: High Growth And High DebtONeil Trader • Tue, May 28 -
-
-
-
-
-
-
-
-
-
-
-
-
-
Watson Pharmaceuticals, Inc. - Shareholder/Analyst CallTue, Jan 24, 2012
-
Watson Pharmaceuticals Q2 2010 Earnings Call TranscriptThu, Aug 5, 2010
-
Watson Pharmaceuticals Q1 2010 Earnings Call TranscriptMon, May 10, 2010
-
Watson Pharmaceuticals, Inc. Q4 2009 Earnings Call TranscriptTue, Feb 23, 2010
-
PR Newswire (Wed, 8:00AM)
-
PR Newswire (Tue, 4:18PM)
-
at CNBC.com (Mon, 6:58PM)
-
at CNBC.com (Mon, 3:58PM)
-
PR Newswire (Mon, 11:48AM)
-
at Fox Business (Thu, 4:02PM)
-
PR Newswire (Jun 11, 2013)
-
PR Newswire (Jun 7, 2013)
-
PR Newswire (Jun 5, 2013)
-
PR Newswire (Jun 4, 2013)
-
PR Newswire (May 24, 2013)
-
PR Newswire (May 24, 2013)
-
at CNBC.com (May 22, 2013)
-
at MarketWatch.com (May 20, 2013)
-
at MarketWatch.com (May 20, 2013)
-
at CNBC.com (May 20, 2013)
-
at CNBC.com (May 20, 2013)
-
at MarketWatch.com (May 20, 2013)
-
at Fox Business (May 20, 2013)
-
at Fox Business (May 20, 2013)
ACT vs. ETF Alternatives
Company Description
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug,... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 14, 1:29 PM Actavis (ACT +1.2%) spikes on reports that the company recently turned away a $15B bid from Mylan (MYL +0.1%). Comment! [Healthcare, On the Move, M&A]
- Monday, May 13, 3:01 PM Buckingham joins in on the Warner Chilcott (WCRX +6%)/Activis (ACT -0.3%) lovefest, upping its price target on Warner to $24, adding that it sees the potential for a debt-financing deal as high as $30 per share for the company. Comment! [Healthcare, On the Move]
- Friday, May 10, 3:07 PM Shares of Activis (ACT +11.4%) and Warner Chilcott (WCRX +24.2%) both resume trading. Comment! [Healthcare, M&A, On the Move]
- Friday, May 10, 12:40 PM More on Actavis (ACT +6.1%) / Warner Chilcott (WCRX +12.3%): The news comes just weeks after ACT broke off merger talks with Valeant Pharmaceuticals (VRX +0.5%) after balking at the premium it was offered. Now, considering the strength of ACT's recent Q1 report, that deal looks dead. Warner, on the other hand, had disclosed over a year ago that it was pursuing a sale. Comment! [Healthcare, M&A, On the Move]
- Friday, May 10, 12:17 PM Shares of Actavis (ACT +3%) spike higher on reports the company is in early-stage talks to acquire Warner Chilcott (WCRX +9.5%). Comment! [Healthcare, M&A, On the Move]
- Monday, April 29, 10:50 AM Although it's a long shot, Goldman's Jami Rubin sees potential synergies in an Actavis (ACT +4%) merger with Valeant (VRX +3.7%). Rubin commented this morning on the activity over the weekend: "While we do not take a view on the likelihood of a transaction being consummated, in our view a potential combined entity would have compelling strategic merit, although we would be surprised by both the timing and the specific combination of companies for various reasons." Comment! [On the Move, M&A, Healthcare]
- Friday, April 26, 12:07 PM Another day, another patent litigation settlement for Actavis (ACT +2.3%). The company says it has reached an agreement with Purdue Pharmaceuticals under which ACT will be licensed to sell "a specific number of bottles of generic OxyContin" beginning early next year assuming the company obtains FDA approval. The deal could potentially mean $100M in gross profits for ACT in 2014 and 2015. (PR) Comment! [On the Move, Healthcare]
- Thursday, April 25, 12:13 PM Actavis (ACT +1%) reaches a settlement with Shire (SHPG +1.6%) regarding an outstanding patent litigation related to ACT's generic version of Intuniv, a treatment for ADHD. Under the terms of the settlement, ACT can launch its generic version of Intuniv on December 1, 2014, or earlier under certain circumstances. SHPG will receive a 25% royalty on gross profits from sales during the period of exclusivity. Comment! [Healthcare, On the Move]
- Friday, October 26, 2012, 3:36 PM Specialty pharmaceutical company Columbia Laboratories (CBRX -41%) gets clobbered today after the FDA denies Watson Pharmaceuticals (WPI -0.5%) formal dispute-resolution request related to its new-drug application for Prochieve, a treatment for the prevention of preterm birth. Watson said it intends to review possible options to continue pursuit of the the drug's development. Comment! [Healthcare, On the Move]
- Thursday, June 28, 2012, 10:53 AM Pharmaceutical stocks are down following the Supreme Court healthcare opinion, although not dramatically: AZN -0.4%, GSK -1.6%, SNY -0.8%, PFE -0.8%, ABT -0.8%, MRK -0.7%, LLY -1%, WPI -0.9%, NVS -0.7%, JNJ -0.4%. iShares Dow Jones US Healthcare ETF (IYH) -0.95%, the Health Care SPDR (XLV) is -1.3%. 2 Comments [Healthcare, On the Move]
- Monday, June 25, 2012, 2:04 PM The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals (WPI +1%), which is acquiring the company, says Goldman. The firm says the news supports its above consensus earnings estimates, adding that it sees only modest impact to TEVA and IPXL. Comment! [Healthcare, On the Move]
- Monday, June 25, 2012, 9:29 AM Shares of drug maker Shire (SHPGY, SHPGF.PK) -13% in London trading on news the FDA approved a generic version of its attention-deficit and hyperactivity drug Adderall XR. Watson Pharma's (WPI) newly acquired Actavis division obtained an abbreviated new-drug application for the generic. SHPGY -12.2%, WPU +1.9% premarket. Comment! [Healthcare, On the Move]
- Tuesday, June 19, 2012, 3:20 PM Watson Pharmaceuticals (WPI +1.8%) gains after being upgraded to Conviction Buy on valuation at Goldman, citing its premium growth and likely tentative approval for Lidoderm. The firm keeps its price target at $87. Comment! [Healthcare, On the Move]
- Tuesday, May 29, 2012, 9:54 AM Endo Health (ENDP +4.8%) settles two patent lawsuits with Watson Pharmaceuticals (WPI +1.8%) that will allow the latter to launch a generic version of Lidoderm, Endo's $1B+ pain-relieving patch, from September 2013, pending FDA approval. Watson will pay Endo a quarter of the gross profit as royalty. Comment! [Healthcare, On the Move]
- Thursday, May 24, 2012, 10:30 AM Watson Pharmaceuticals (WPI +2.8%) gains on an upgrade to Outperform on valuation at Wells Fargo. Wells says that on deeper analysis, it has higher confidence in the company's ability to hit EPS targets following the Actavis acquisition. The firm also raises its price target range to $84 - $90 from $75 - $79. Comment! [Healthcare, On the Move]
- Thursday, April 26, 2012, 1:20 PM Watson Pharmaceuticals (WPI +6.6%) gets a lift today after agreeing to acquire Swiss rival Actavis. The purchase gives the company a boost in the global rankings of generic drug makers to the number 3 spot. Citigroup upgrades the stock to Buy on the news. Comment! [Healthcare, On the Move, M&A]
-
ONeil Trader
$VRX Bausch + Lomb acquisition impact http://goo.gl/YIuHH $ACT high growth vs high debt - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 1 replies
-
Michael Bryant: Long $SPWR. I may soon go long $ACT. And what's up with $WWWW? Second day it rose on unusual volume.
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Michael Bryant
Pharmaceutical maker Actavis ($ACT) seems to have broken out back in 2010 and is marching higher. http://yhoo.it/15E0yBl;c= - View all 0 replies
-
- View all 1 replies
-
Michael Bryant: $DDD and $GMCR are great companies and probably stocks, too. Love $GMCR coffeemaker.
-
The Wall Street Transcript
Actavis ($ACT) Has Large Exposure to Generic Drugs in Alternative Dosage Forms- http://su.pr/2eStTL - View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-
Michael Bryant: Long $SPWR. I may soon go long $ACT. And what's up with $WWWW? Second day it rose on unusual volume.
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
Michael Bryant: $DDD and $GMCR are great companies and probably stocks, too. Love $GMCR coffeemaker.
-
- View all 1 replies
-
-
Ryan Mallory
There's A Storm Coming Mr. Wayne: My Short Watch-List $ELLI $ANN $ACT http://bit.ly/WZ5eaf - View all 3 replies
-
-
-
- View all 1 replies
-
-
Capitalist Bull
Traditional Technical Patterns completing & readying to #Breakout..$AAPL $GOOG $CLMT $REGN $RYL $BIDU $ALXN $ACT & more http://bit.ly/MwUXlb - View all 1 replies
-